Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 5016 | Ordered by Date (descending)
1 2 3 ... 49 50 51  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cellares–8VC: investment, 202105 financing round Series B totalling $82m incl existing + co-investor 8VC 2021-05-05
Cellares–Decheng Capital: investment, 202105 financing round Series B totalling $82m incl new + lead investor Decheng Capital 2021-05-05
Cellares–Eclipse Ventures: investment, 202105 financing round Series B totalling $82m incl existing + co-lead investor Eclipse Ventures 2021-05-05
Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures 2021-05-05
Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science 2021-05-05
Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial 2021-05-05
Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital 2021-05-05
Athenex–Cooley: legal services, 202105 supply service Cooley (UK) acted as sole advisor to Athenex with regard to acquisition of Kuur Therapeutics 2021-05-04
Kuur Therapeutics–Athenex: investment, 202105 acquisition $70m upfront (mainly in shares) + $115m milestones by Athenex 2021-05-04
Kuur Therapeutics–HMB Legal Counsel: legal services, 202105 supply service HMB Legal legal advisor to Kuur with regard to acquisition by Athenex 2021-05-04
Kuur Therapeutics–SVB: financial services, 202105 supply service SVB Lerrink financial adivsor to Kuur with regard to acquisition by Athenex 2021-05-04
Oxford Nanopore–SEVERAL: investment, 202105 financing round £195m from new + existing investors 2021-05-04
Aquila Biolabs–Scientific Industries: investment, 202104 acquisition of Aquila Biolabs GmbH by Scientific Bioprocessing Inc 2021-04-30
Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management 2021-04-29
Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital 2021-04-29
Forge Biologics–SEVERAL: investment, 202104 financing round Series B $120m led by RA Capital 2021-04-29
Valneva–SEVERAL: investment, 202104– European private placement ANNOUNCED 2021-04-29
Valneva–SEVERAL: investment, 202104– US IPO of ADSs at Nasdaq Global Market ANNOUNCED 2021-04-29
Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe 2021-04-28
Kaia Health–3VC: investment, 202104 financing round Series C totalling $75m incl existing + co-investor 3VC 2021-04-28
Kaia Health–A Round Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor A Round Capital 2021-04-28
Kaia Health–Balderton Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Balderton Capital 2021-04-28
Kaia Health–Eurazeo: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Eurazeo 2021-04-28
Kaia Health–Heartcore Capital: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Heartcore Capital 2021-04-28
Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR 2021-04-28
Kaia Health–OTHER: investment, 202104 financing round Series C totalling $75m incl undisclosed growth equity fund as lead investor 2021-04-28
Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund 2021-04-28
Kaia Health–Symphony Ventures: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Symphony Ventures 2021-04-28
Kaia Health–UnitedHealth: investment, 202104 financing round Series C totalling $75m incl existing + co-investor Optum Ventures 2021-04-28
Exscientia–BlackRock: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BlackRock 2021-04-27
Exscientia–BMS: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BMS 2021-04-27
Exscientia–Casdin Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Casdin Capital 2021-04-27
Exscientia–Farallon Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Farallon Capital 2021-04-27
Exscientia–GT Healthcare Capital Partners: investment, 202104 financing round Series D totalling $225m incl co-investor GT Healthcare 2021-04-27
Exscientia–Hongkou: investment, 202104 financing round Series D totalling $225m incl co-investor Hongkou 2021-04-27
Exscientia–Laurion Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Laurion Capital 2021-04-27
Exscientia–Marshall Wace: investment, 202104 financing round Series D totalling $225m incl co-investor Marshall Wace 2021-04-27
Exscientia–Nan Fung: investment, 202104 financing round Series D totalling $225m incl co-investor Pivotal bioVenture Partners 2021-04-27
Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings 2021-04-27
Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104 financing round Series D totalling $225m incl lead investor SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104– equity commitment up to $300m by SoftBank than can be drawn at Exscientia’s discretion 2021-04-27
Exscientia–United Arab Emirates (govt): investment, 202104 financing round Series D totalling $225m incl co-investor Mubadala Investment Company 2021-04-27
Molecular Partners–SEVERAL: investment, 202104– US IPO at Nasdaq FILED 2021-04-23
Anavo Therapeutics–MacDougall Advisors: public relations, 202104 service existent by MacDougall 2021-04-22
Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I 2021-04-20
Forbion–Wealth Management Partners: investment, 202104 final closing at €360m of Forbion Growth Opportunities Fund I incl investor WMP 2021-04-20
Mestag Therapeutics–JnJ: investment, 202104 seed financing round totalling $11m incl Johnson & Johnson Innovation JJDC Inc 2021-04-20
Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC 2021-04-20
Sense Biodetection–Koch Industries: investment, 202104 financing round Series B totalling $50m incl new + lead investor Koch Disruptive Technologies 2021-04-20
Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies 2021-04-20
Lumicks–Farallon Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Farallon Capital 2021-04-16
Lumicks–Irving Investors: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Irving Investors 2021-04-16
Lumicks–Lauxera Capital: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co-lead investor Lauxera Capital 2021-04-16
Lumicks–Parian Global Management: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Parian Global Mgt 2021-04-16
Lumicks–Pura Vida Investments: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Pura Vida 2021-04-16
Lumicks–SEVERAL: investment, 202104 financing round Series D $93m preferred shares led by Farallon Capital + Lauxera Capital 2021-04-16
Lumicks–Softbank: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor Softbank Vision 2 2021-04-16
Lumicks–T Rowe Price: investment, 202104 financing round Series D totalling $93m preferred shares incl new + co investor funds managed by T Rowe Price 2021-04-16
Alchemab–RA Capital: investment, 202104 financing round Series B totalling £60m incl lead investor RA Capital Management 2021-04-15
Alchemab–SEVERAL: investment, 202104 financing round Series B £60m led by RA Capital Management 2021-04-15
Alligator Bioscience–MacroGenics: antibody cancer drug, 202104– collab research using Neo-X-Prime plus DART+TRIDENT technologies against two targets 2021-04-15
ATMPS–Oribiotech: CAGT manufacturing technology, 202104– collab ww for integrated digital patform for CAGT developers using Hataali platform 2021-04-14
Jaguar Gene Therapy–SEVERAL: investment, 202104 financing round Series B $139m co-led by Eli Lilly + Deerfield Management 2021-04-13
Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group 2021-04-13
Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al 2021-04-13
Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers 2021-04-13
Luminex–DiaSorin: investment, 202104– acquisition $1.8b in cash for $37/share by DiaSorin ANNOUNCED 2021-04-11
Tidal Therapeutics–Sanofi: investment, 202104 acquisition $160m upfront + $310m milestones by Sanofi 2021-04-09
Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED 2021-04-08
Metagenomi–RA Capital: investment, 202104 financing round Series A extension totalling $10m incl new investor RA Capital Management 2021-04-07
Metagenomi–SEVERAL: investment, 202104 financing round Series A extension $10m with RA Capital Management closing total Series A at $75m 2021-04-07
OncoResponse–Helsinn: investment, 202103 financing round Series C totalling $40.6m incl existing + co-investor 3B Future Health Fund 2021-03-31
OncoResponse–SEVERAL: investment, 202103 financing round Series C $40.6m led by Magnetar Group 2021-03-31
Pyxis Oncology–LifeSci: public relations, 202103 supply service existent by LifeSci Communications 2021-03-30
Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience 2021-03-30
Gyroscope Therapeutics–Cambridge Innovation Capital: investment, 202103 financing round Series C totalling $148m incl co-investor CIC 2021-03-26
Gyroscope Therapeutics–Fosun: investment, 202103 financing round Series C totalling $148m incl co-investor Fosun Pharma 2021-03-26
Gyroscope Therapeutics–OTHER: investment, 202103 financing round Series C totalling $148m incl co-investor undisclosed healthcare focused fund 2021-03-26
Gyroscope Therapeutics–SEVERAL: investment, 202103 financing round Series C $148m led by Forbion Growth I 2021-03-26
Gyroscope Therapeutics–Sofinnova: investment, 202103 financing round Series C totalling $148m incl co-investor Sofinnova Investments 2021-03-26
Gyroscope Therapeutics–Syncona: investment, 202103 financing round Series C totalling $148m incl existing + co-investor Syncona 2021-03-26
Gyroscope Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $148m incl co-investor T Rowe Price Associates Inc 2021-03-26
Gyroscope Therapeutics–Tetragon Financial Group: investment, 202103 financing round Series C totalling $148m incl co-investor TFG 2021-03-26
Dropprint Genomics––Immunai: investment, 202103 acquisition of Dropprint Genomics by Immunai 2021-03-25
Leyden Laboratories–Alphabet: investment, 202103 financing round Series A totalling €40m incl lead investor GV 2021-03-25
Leyden Laboratories–Brook Byers: investment, 202103 financing round Series A totalling €40m incl co-investor Brook Byers 2021-03-25
Leyden Laboratories–Casdin Capital: investment, 202103 financing round Series A totalling €40m incl co-investor Casdin Capital 2021-03-25
Leyden Laboratories–F-Prime: investment, 202103 financing round Series A totalling €40m incl co-investor F-Prime 2021-03-25
Leyden Laboratories–LifeSci: public relations, 202103 supply service existent by LifeSci Communications 2021-03-25
Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV 2021-03-25
Scipher Medicine–Alumni Ventures: investment, 202103 financing round Series C totalling $82m incl exisiting + co-investor Alumni Ventures 2021-03-24
Scipher Medicine–aMoon: investment, 202103 financing round Series C totalling $82m incl co-lead investor aMoon 2021-03-24
Scipher Medicine–Echo Health Ventures: investment, 202103 financing round Series C totalling $82m incl co-investor Echo Health Ventures 2021-03-24
Scipher Medicine–Khosla Ventures: investment, 202103 financing round Series C totalling $82m incl exisiting + co-investor Khosla Ventures 2021-03-24
Scipher Medicine–Northpond Ventures: investment, 202103 financing round Series C totalling $82m incl co-lead investor Northpond Ventures 2021-03-24
Scipher Medicine–SEVERAL: investment, 202103 financing round Series C $82m co-led by aMoon + Northpond Ventures 2021-03-24
1910 Genetics–SEVERAL: investment, 202103 financing round Series A $22m co-led by M12 + Playground Global 2021-03-23
Dunad Therapeutics–Epidarex Capital: investment, 2020–202103 Dunad emerges from stealh with seed financing from Epidarex Capital 2021-03-23
Dunad Therapeutics–Huntsworth: public relations, 202103 service existent by Citigate Dewe Rogerson 2021-03-23
1 2 3 ... 49 50 51  next pagenext page



Advertisement

Picture [iito] Made Without Love 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture [iito] Made Without Love 650x80px

» top